American Society of Hirudotherapy

High-resolution structure of a Kazal-type serine protease inhibitor from the dengue vector Aedes aegypti

Research article published in Acta crystallographica. Section F, Structural biology communications (2017)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Preclinical (animal)Genomics & ProteomicsTorquato et al. · Acta crystallographica. Section F, Structural biology communications, 2017

Abstract

Blood-feeding exoparasites are rich sources of protease inhibitors, and the mosquito Aedes aegypti, which is a vector of Dengue virus, Yellow fever virus, Chikungunya virus and Zika virus, is no exception. AaTI is a single-domain, noncanonical Kazal-type serine proteinase inhibitor from A. aegypti that recognizes both digestive trypsin-like serine proteinases and the central protease in blood clotting, thrombin, albeit with an affinity that is three orders of magnitude lower. Here, the 1.4 Å resolution crystal structure of AaTI is reported from extremely tightly packed crystals (∼22% solvent content), revealing the structural determinants for the observed inhibitory profile of this molecule.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAedesAmino Acid SequenceAnimalsBinding SitesCloning, MolecularCrystallography, X-RayGene ExpressionGenetic VectorsInsect ProteinsInsect VectorsMolecular Docking SimulationPichiaProtein BindingProtein Conformation, alpha-HelicalProtein Conformation, beta-StrandProtein Interaction Domains and MotifsProtein MultimerizationRecombinant ProteinsSequence AlignmentSequence Homology, Amino AcidSerine Peptidase Inhibitors, Kazal TypeThrombin

Summary

The 1.4 Å crystal structure of AaTI, a Kazal-type serine protease inhibitor from the dengue vector Aedes aegypti that targets trypsin-like proteases and thrombin, is reported, revealing the structural basis of its inhibitory profile.

Context

This structural-biology study solved the 1.4 A crystal structure of AaTI, a noncanonical Kazal-type serine protease inhibitor from the mosquito Aedes aegypti, showing it inhibits both digestive trypsin-like proteases and the clotting enzyme thrombin (the latter with roughly three orders of magnitude lower affinity). The conceptual overlap with hirudotherapy is thematic: blood-feeding organisms are recurrent sources of anticoagulant protease inhibitors, and Kazal-type inhibitors also occur in the leech secretome. AaTI is a mosquito protein, not a Hirudo medicinalis leech compound. This is a purely structural/in-vitro characterization of a non-leech protein, with no animal or clinical data.

Citation

Reference (Vancouver style)

Torquato RJS, Lu S, Martins NH, Tanaka AS, Pereira PJB. High-resolution structure of a Kazal-type serine protease inhibitor from the dengue vector Aedes aegypti. Acta Crystallogr F Struct Biol Commun. 2017;73(Pt 8):469-475. doi:10.1107/S2053230X17010007. PMID: 28777090

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.